📊 Midday Market Take

Hey there, hope your Thursday afternoon is treating you well. The S&P 500 is nudging up 0.34% and the Dow is having a genuinely good day, up 1.62%, while the Nasdaq slipped just slightly into the red.

The Dow's strength points to industrials and blue chips carrying the load today, which usually signals a rotation out of growth names. Keep an eye on whether tech can recover that small loss before the closing bell, because that story could set the tone for Friday.

Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

3 Reasons to Watch LQDA

• Earnings Estimates Are Climbing Fast. Analysts are revising their earnings estimates for Liquidia upward, which historically signals that a stock is building real fundamental momentum, not just hype. When the money people start bumping their numbers, it usually means the business is quietly outperforming expectations.
• A Year of Jaw-Dropping Price Performance. LQDA is up 267% over the past year, and the momentum has not cooled off, with shares gaining another 73% in just the last 30 days and jumping over 16% in a single session today. That kind of sustained, accelerating move across multiple timeframes is the kind of chart pattern that gets serious investors to pay attention.
• Rare Disease Focus Draws Institutional Eyes. Liquidia is presenting at the Jefferies Global Healthcare Conference, putting its pulmonary arterial hypertension pipeline, including lead product YUTREPIA and the Phase III candidate L606, in front of exactly the institutional investors who move markets. Getting a stage at a major healthcare conference while your stock is in full momentum mode is a combination that tends to keep buyers interested.

Top Market Headlines

Is Helios Technologies (HLIO) Outperforming Other Industrial Products Stocks This Year?

Here is how Helios Technologies (HLIO) and Luxfer (LXFR) have performed compared to their sector so far this year.

Trump’s new AI budget just passed — one stock could soar (Ad)

In a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budget in history.

Oil prices inch back toward $100 a barrel as U.S. stocks retreat from records

Oil prices rose Wednesday following the latest flare-up in fighting to threaten the U.S.-Iran ceasefire, and U.S. stocks retreated from their records.

Which of These 3 Software Stocks Is Most Likely to Be Acquired in 2026?

Public SaaS valuations have compressed over two years while private equity dry powder and strategic acquirer balance sheets remain robust, and that...

Futurist Eric Fry says it will be a "Season of Surge" for these three stocks (Ad)

One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.

2 Warren Buffett Dividend Stocks to Buy Now

Warren Buffett appreciates companies that make dividend growth a priority.

Flood Into Gold (Ad)

An innovation in gold investing is about to unleash trillions in fresh demand - giving ordinary savers the ability to move their money into gold instantly, without storage fees. When this system goes live in 2026, the ripple effects could send four specific gold stocks soaring 100X over the next decade.